FDA
-
-
-
-
-
-
-
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
-
-
-
-
-
-
-
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
-
-
-
-
-
-
-
Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
-
-
-
-
-
-
-
Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
-
-
-
-
-
-
-
Cellectar Biosciences (CLRB) Announces One-for-Thirty Reverse Stock Split
-
-
-
-
-
-
-
Cellectar Biosciences (CLRB) Granted FDA Breakthrough Therapy Designation for Iopofosine I 131
-
329,984 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

